📊 BICX Key Takeaways
Investment Thesis
BioCorRx is in severe financial distress with negative stockholders' equity of -$13.5M, indicating the company is technically insolvent. Revenue has collapsed 92.8% year-over-year to just $948.4K while operating losses of -$4.3M persist, demonstrating a non-viable business model. With only $287.7K in cash, a current ratio of 0.10x, and negative operating cash flow of -$1.5M, the company faces imminent liquidity crisis and potential bankruptcy.
BICX Strengths
- Gross margin of 67.9% indicates products/services retain pricing power when sold
- Zero long-term debt eliminates debt service obligations
- Specialty outpatient facilities sector has structural demand drivers
BICX Risks
- Negative stockholders' equity of -$13.5M represents technical insolvency and shareholder value destruction
- Revenue decline of 92.8% YoY indicates loss of core business or market rejection
- Critical liquidity crisis: $287.7K cash against $20.3M liabilities with current ratio of 0.10x
- Negative operating cash flow of -$1.5M with minimal cash reserves means days to months of runway
- Operating losses of -$4.3M on $948.4K revenue indicates fundamentally broken unit economics
- No insider buying activity in last 90 days suggests management lacks confidence
Key Metrics to Watch
- Cash balance and runway to insolvency
- Revenue stabilization or further deterioration
- Operating cash flow trajectory and burn rate
- Debt covenant compliance and bankruptcy filing risk
BICX Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BICX Profitability Ratios
BICX vs Default Sector
How BioCorRx Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BICX Balance Sheet & Liquidity
BICX 5-Year Financial Trend
5-Year Trend Summary: BioCorRx Inc.'s revenue has declined by 63% over the 5-year period, indicating business contraction.
BICX Growth Metrics (YoY)
BICX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.5M | $-0.11 |
| Q2 2025 | $4.0K | -$1.2M | $-0.07 |
| Q3 2024 | N/A | -$867.3K | N/A |
| Q2 2024 | $4.0K | -$923.5K | N/A |
| Q1 2024 | $3.6K | -$841.4K | N/A |
| Q3 2023 | $10.1K | -$867.3K | N/A |
| Q2 2023 | $16.0K | -$923.5K | N/A |
| Q1 2023 | $20.5K | -$945.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BICX Capital Allocation
BICX SEC Filings
Access official SEC EDGAR filings for BioCorRx Inc. (CIK: 0001443863)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BICX
What is the AI rating for BICX?
BioCorRx Inc. (BICX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BICX's key strengths?
Gross margin of 67.9% indicates products/services retain pricing power when sold. Zero long-term debt eliminates debt service obligations.
What are the risks of investing in BICX?
Negative stockholders' equity of -$13.5M represents technical insolvency and shareholder value destruction. Revenue decline of 92.8% YoY indicates loss of core business or market rejection.
What is BICX's revenue and growth?
BioCorRx Inc. reported revenue of $948.4K.
Does BICX pay dividends?
BioCorRx Inc. does not currently pay dividends.
Where can I find BICX SEC filings?
Official SEC filings for BioCorRx Inc. (CIK: 0001443863) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BICX's EPS?
BioCorRx Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.